309 related articles for article (PubMed ID: 27912913)
21. Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab: Findings from the TREX-AMD Trial.
Abdelfattah NS; Al-Sheikh M; Pitetta S; Mousa A; Sadda SR; Wykoff CC;
Ophthalmology; 2017 Feb; 124(2):215-223. PubMed ID: 27863845
[TBL] [Abstract][Full Text] [Related]
22. Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab.
Cho H; Shah CP; Weber M; Heier JS
Br J Ophthalmol; 2013 Aug; 97(8):1032-5. PubMed ID: 23766432
[TBL] [Abstract][Full Text] [Related]
23. Intravitreal aflibercept for ranibizumab-resistant exudative age-related macular degeneration with choroidal vascular hyperpermeability.
Nomura Y; Yanagi Y
Jpn J Ophthalmol; 2015 Jul; 59(4):261-5. PubMed ID: 25983109
[TBL] [Abstract][Full Text] [Related]
24. Variable response of subretinal hyperreflective material to anti-vascular endothelial growth factor classified with optical coherence tomography angiography.
Maruyama-Inoue M; Sato S; Yamane S; Kadonosono K
Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2089-2096. PubMed ID: 30173338
[TBL] [Abstract][Full Text] [Related]
25. PROGNOSTIC VALUE OF HYPERREFLECTIVE FOCI IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION TREATED WITH BEVACIZUMAB.
Segal O; Barayev E; Nemet AY; Geffen N; Vainer I; Mimouni M
Retina; 2016 Nov; 36(11):2175-2182. PubMed ID: 27078799
[TBL] [Abstract][Full Text] [Related]
26. Radial versus raster spectral-domain optical coherence tomography scan patterns for detection of macular fluid in neovascular age-related macular degeneration.
Adam MK; Rayess N; Rahimy E; Maguire JI; Hsu J
Br J Ophthalmol; 2016 Apr; 100(4):491-4. PubMed ID: 26261232
[TBL] [Abstract][Full Text] [Related]
27. Subretinal hyperreflective exudation associated with neovascular age-related macular degeneration.
Shah VP; Shah SA; Mrejen S; Freund KB
Retina; 2014 Jul; 34(7):1281-8. PubMed ID: 24695062
[TBL] [Abstract][Full Text] [Related]
28. EFFICACY OF ADJUVANT TOPICAL DORZOLAMIDE-TIMOLOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
Lee JH; Lee SC; Byeon SH; Koh HJ; Kim SS; Lee CS
Retina; 2019 Oct; 39(10):1953-1958. PubMed ID: 30161096
[TBL] [Abstract][Full Text] [Related]
29. Comparative Retinal Vessel Size Study of Intravitreal Ranibizumab and Bevacizumab in Eyes with Neovascular Age-Related Macular Degeneration.
Kurt MM; Çekiç O; Akpolat Ç; Aslankurt M; Elçioğlu MN
Ophthalmologica; 2017; 238(3):147-153. PubMed ID: 28601887
[TBL] [Abstract][Full Text] [Related]
30. Early Changes of Retinal Morphology in Therapy of Neovascular Age-Related Macular Degeneration with Three Commonly Used Anti-VEGF Agents.
Enders P; Sitnilska V; Altay L; Fauser S
Ophthalmologica; 2018; 239(1):45-51. PubMed ID: 28950272
[TBL] [Abstract][Full Text] [Related]
31. Differential Response to Anti-VEGF Regimens in Age-Related Macular Degeneration Patients with Early Persistent Retinal Fluid.
Jaffe GJ; Kaiser PK; Thompson D; Gibson A; Saroj N; Vitti R; Berliner AJ; Heier JS
Ophthalmology; 2016 Sep; 123(9):1856-64. PubMed ID: 27369111
[TBL] [Abstract][Full Text] [Related]
32. Changes in Fundus Autofluorescence after Anti-vascular Endothelial Growth Factor According to the Type of Choroidal Neovascularization in Age-related Macular Degeneration.
Lee JY; Chung H; Kim HC
Korean J Ophthalmol; 2016 Feb; 30(1):17-24. PubMed ID: 26865799
[TBL] [Abstract][Full Text] [Related]
33. Quantification of the therapeutic response of intraretinal, subretinal, and subpigment epithelial compartments in exudative AMD during anti-VEGF therapy.
Golbaz I; Ahlers C; Stock G; Schütze C; Schriefl S; Schlanitz F; Simader C; Prünte C; Schmidt-Erfurth UM
Invest Ophthalmol Vis Sci; 2011 Mar; 52(3):1599-605. PubMed ID: 21051733
[TBL] [Abstract][Full Text] [Related]
34. One-year outcome of intravitreal ziv-aflibercept therapy for non-responsive neovascular age-related macular degeneration.
Braimah IZ; Agarwal K; Mansour A; Chhablani J;
Br J Ophthalmol; 2018 Jan; 102(1):91-96. PubMed ID: 28596286
[TBL] [Abstract][Full Text] [Related]
35. Gray hyper-reflective subretinal exudative lesions in exudative age-related macular degeneration.
Ores R; Puche N; Querques G; Blanco-Garavito R; Merle B; Coscas G; Oubraham H; Semoun O; Souied EH
Am J Ophthalmol; 2014 Aug; 158(2):354-61. PubMed ID: 24794284
[TBL] [Abstract][Full Text] [Related]
36. Fixation stability measurements in patients with neovascular age-related macular degeneration treated with ranibizumab.
Grenga PL; Fragiotta S; Meduri A; Lupo S; Marenco M; Vingolo EM
Can J Ophthalmol; 2013 Oct; 48(5):394-9. PubMed ID: 24093186
[TBL] [Abstract][Full Text] [Related]
37. Association between choroidal thickness and the response to intravitreal ranibizumab injection in age-related macular degeneration.
Shin JY; Kwon KY; Byeon SH
Acta Ophthalmol; 2015 Sep; 93(6):524-32. PubMed ID: 25581639
[TBL] [Abstract][Full Text] [Related]
38. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
39. REGRESSION OF TYPE 2 NEOVASCULARIZATION INTO A TYPE 1 PATTERN AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Dolz-Marco R; Phasukkijwatana N; Sarraf D; Freund KB
Retina; 2017 Feb; 37(2):222-233. PubMed ID: 27627752
[TBL] [Abstract][Full Text] [Related]
40. The Presence of Intra- or Subretinal Fluid during the Loading Phase in the Treatment of Exudative Age-Related Macular Degeneration with Intravitreal Ranibizumab Assessed by Optical Coherence Tomography.
Ebneter A; Gekkiev B; Chanana B; Wolf S; Zinkernagel MS
Ophthalmologica; 2015; 234(2):61-6. PubMed ID: 25998752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
